InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
April 25, 2023 19:19 ET
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading...
InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel
April 24, 2023 17:59 ET
|
InterCure Ltd.
NEW YORK, TORONTO, and HERZLIYA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading...
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries
April 20, 2023 08:30 ET
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, April 20, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading...
InterCure Reschedules 2022 Full Year Results Conference Call
April 03, 2023 15:27 ET
|
InterCure Ltd.
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that...
InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results
March 31, 2023 20:00 ET
|
InterCure Ltd.
Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from...
InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
February 14, 2023 08:30 ET
|
InterCure Ltd.
NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) the biggest and most...
InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)
February 01, 2023 08:30 ET
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") announces that,...
InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"
December 19, 2022 08:30 ET
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the largest and...
InterCure to Participate in Cowen 5th Annual Cannabis Conference
December 08, 2022 09:30 ET
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 08, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that...
InterCure Announces the Withdrawal of a Class Action Lawsuit against it
December 05, 2022 16:30 ET
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to...